Respiratory News and Research RSS Feed - Respiratory News and Research

Ruthigen, Pulmatrix sign definitive merger agreement

Ruthigen, Pulmatrix sign definitive merger agreement

Ruthigen, Inc., a biopharmaceutical company, and Pulmatrix, Inc., a Lexington, Massachusetts based clinical stage biotechnology company, announced today that on March 13, 2015, they have entered into a definitive merger agreement. [More]
Meta-analysis finds that high dose zinc acetate lozenges may help reduce duration of cold symptoms

Meta-analysis finds that high dose zinc acetate lozenges may help reduce duration of cold symptoms

According to a meta-analysis published in BMC Family Practice, high dose zinc acetate lozenges shortened the duration of common-cold associated nasal discharge by 34%, nasal congestion by 37%, scratchy throat by 33%, and cough by 46%. [More]
Exposure to diesel exhaust may exacerbate respiratory diseases

Exposure to diesel exhaust may exacerbate respiratory diseases

Researchers in the UK have, for the first time, shown how exhaust pollution from diesel engines is able to affect nerves within the lung. Air pollution is a significant threat to health, they say, and identifying potential mechanisms linking exposure to diesel exhaust and the exacerbation of respiratory diseases may lead to treatments for those affected. [More]
Antibiotic nanoparticles can help treat lung infection, prevent drug resistance

Antibiotic nanoparticles can help treat lung infection, prevent drug resistance

Treating respiratory disease is often difficult because drugs have to cross biological barriers such as respiratory tissue and mucosa, and must therefore be given in large quantities in order for an effective amount to reach the target. [More]
Gottlieb Allergy Count kicks off its first report of 2015

Gottlieb Allergy Count kicks off its first report of 2015

Those in the Midwest with sensitive respiratory systems will find relief beginning Monday, March 16 as the Gottlieb Allergy Count kicks off its first report of 2015. The Gottlieb Allergy Count is the official daily allergy count for the Midwest. [More]
TRMC expands use of capnography to monitor patients during moderate sedation

TRMC expands use of capnography to monitor patients during moderate sedation

Tillamook Regional Medical Center recently strengthened patient safety measures by expanding its use of capnography to monitor patients during moderate sedation. Sedation is commonly used during procedures such as colonoscopies and in some instances can suppress breathing. [More]
More research needed to explore toxicity of cellulose nanocrystals, says Virginia Tech scientist

More research needed to explore toxicity of cellulose nanocrystals, says Virginia Tech scientist

Are cellulose nanocrystals harmful to human health? The answer might depend on the route of exposure, according to a review of the literature by a Virginia Tech scientist, but there have been few studies and many questions remain. [More]
Early mobility therapy improves outcomes of patients with acute respiratory distress syndrome

Early mobility therapy improves outcomes of patients with acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is a life-threatening lung condition that affects approximately 200,000 people a year in the United States and has a higher mortality rate than breast and prostate cancer combined. The condition most often occurs in people who are critically ill or who have significant injuries; those who do survive it often experience profound skeletal muscle weakness. [More]
Repeatedly exposing children to secondhand smoke is child abuse, argues Adam Goldstein

Repeatedly exposing children to secondhand smoke is child abuse, argues Adam Goldstein

Purposefully and repeatedly exposing children to secondhand smoke — a known human carcinogen — is child abuse, according to an opinion piece written by Adam Goldstein, MD, MPH, a professor in the Department of Family Medicine at the University of North Carolina School of Medicine. [More]
Study evaluates effectiveness of surgical vs nonsurgical treatment for proximal humeral fractures

Study evaluates effectiveness of surgical vs nonsurgical treatment for proximal humeral fractures

Among patients with a displaced fracture in the upper arm near the shoulder (proximal humeral), there was no significant difference between surgical treatment and nonsurgical treatment in patient-reported outcomes over two years following the fracture, results that do not support the trend of increased surgery for patients with this type of fracture, according to a study in the March 10 issue of JAMA. [More]
Inhaled Nitric Oxide still being used in preterm neonates despite evidence of short-term benefit

Inhaled Nitric Oxide still being used in preterm neonates despite evidence of short-term benefit

Inhaled Nitric Oxide (iNO) is a drug approved by the Food and Drug Administration that is commonly used in term and near-term neonates who have severe respiratory failure caused by pulmonary hypertension. Over the last decade there have been multiple large studies trying to determine a clinical use for iNO in preterm neonates, but despite evidence of short-term benefit, this drug has not been shown to improve long-term outcomes in preemies. [More]
Halyard Health releases improved placement kit for PEG tube

Halyard Health releases improved placement kit for PEG tube

Halyard Health, formerly Kimberly-Clark Health Care, today announced the introduction of an improved placement kit for its Percutaneous Endoscopic Gastrostomy (PEG) tube, the MIC* PEG tube. The components of the kit have been organized to align with the procedural steps for tube placement. [More]
Blood gas testing: an interview with David Stein, PhD, CEO, Point of Care, Siemens Healthcare Diagnostics

Blood gas testing: an interview with David Stein, PhD, CEO, Point of Care, Siemens Healthcare Diagnostics

The industry term ‘blood gas testing’ has come to mean the accurate measurement and reporting of a wide menu of blood parameters, all on a single platform. [More]
FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). [More]
Preventing lung infections in childhood could help people with cystic fibrosis during adulthood

Preventing lung infections in childhood could help people with cystic fibrosis during adulthood

Preventing lung infections in childhood could stop later life-threatening infections for people with cystic fibrosis (CF), according to the latest research carried out at Aston University. [More]
Mallinckrodt enters into definitive agreement to acquire Ikaria

Mallinckrodt enters into definitive agreement to acquire Ikaria

Mallinckrodt plc, a leading global specialty biopharmaceutical company, and Ikaria, Inc. a privately-held critical care company, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria, Inc. from a Madison Dearborn-led investor group in a transaction valued at approximately $2.3 billion. [More]
Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration. [More]
Halyard Health's net sales increase 2% to $439 million in fourth quarter 2014

Halyard Health's net sales increase 2% to $439 million in fourth quarter 2014

Halyard Health, Inc. today reported year-end 2014 results and provided its 2015 outlook and related key planning assumptions. [More]
Novogen's TRXE-009 therapy shows promise against brain cancer

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer. [More]
UF researchers find that people with brain tumor fare better with personal insurance

UF researchers find that people with brain tumor fare better with personal insurance

Brain tumor patients who are uninsured or use Medicaid stay hospitalized longer and develop more medical complications than those with private insurance, University of Florida Health researchers have found. [More]
Advertisement
Advertisement